Targeting escape mutations
in hematological cancers
with first and best in class medicines
A small molecule oncology drug discovery company that is committed to defeating cancer.
At Eilean Therapeutics we are developing pan-variant therapies for hematologic malignancies that target the major drivers of cancer resistance, helping to overcome the limitations of current oncology therapeutics.
Our Recent Publications
Eilean Therapeutics Announces Upcoming Presentation of a First-in-Class MALT1 Degrader at ASH Annual Meeting
Eilean Therapeutics Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML® Master Clinical Trial
